News
Noel Courage and Nyrie Israelian coauthored the article “The scope of Canadian patented drug price reviews narrow” published by The Patent Lawyer Magazine
February 28, 2022
“Noel Courage and Nyrie Israelian, of Bereskin & Parr, summarize a recent case which reviewed the pricing of the Alexion drug Soliris, resulting in a strengthened position for innovator drug companies undergoing pricing review.”
Click here for the full article.
This article was first published in the January/February 2022 issue of the Patent Lawyer Magazine
